Polyclonal Antibody to Receptor Interacting Serine Threonine Kinase 2 (RIPK2)
| Code | Size | Price |
|---|
| PAB786Mu01-20ul | 20ul | £86.00 |
Quantity:
| PAB786Mu01-100ul | 100ul | £158.00 |
Quantity:
| PAB786Mu01-200ul | 200ul | £214.00 |
Quantity:
| PAB786Mu01-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CCK; CARD3; CARDIAK; GIG30; RICK; RIP2; CARD-containing interleukin-1 beta-converting enzyme-associated kinase; Receptor-interacting 2; RIP-like-interacting CLARP kinase
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Receptor Interacting Serine Threonine Kinase 2
Reactivity:
Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL<br/>Immunohistochemistry: 5-20ug/mL<br/>Immunocytochemistry: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Receptor Interacting Serine Threonine Kinase 2 (RIPK2) | RPB786Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||